Announcements Trials
Browse Landscape

Phase

Phase 1 52Phase NA 21Phase 1/2 18Phase 2 14Phase 4 2Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 118Breast 8Gastrointestinal 5Plasma cell 2NET 2Endocrine 2Dermatologic 2Thoracic 1Sarcoma 1Other 1Gynecologic 1Classical hematology 1

Conditions

Keratosis, Actinic 46Melanoma 27Skin Neoplasms 14Carcinoma, Basal Cell 9Lymphoma, T-Cell, Cutaneous 8Neoplasm Metastasis 5Mycosis Fungoides 5Lung Neoplasms 5Keratosis 5Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma 3Breast Neoplasms 3Uveal Melanoma 2Skin Diseases 2Sezary Syndrome 2Prostatic Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Subcutaneous panniculitis-like T-cell lymphoma 1Squamous Cell Carcinoma of Head and Neck 1Skin Substitutes 1Seroma 1Renal Transplant Patients at High-risk for Skin Cancer 1Psoriasis 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1

Interventions

pasireotide 1Sevoflurane 1Propofol 1Isoflurane 1Desflurane 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Prostatic Neoplasms × Dermatologic × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT04074460 2022-06-09

VAPOR-C

Peter MacCallum Cancer Centre, Australia

Phase 4 Completed
169 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡